Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
30 results
D1.306 - Cold-induced urticaria: Phenotypic characterization and risk factors for cold-induced anaphylaxis
D1.307 - Lipid metabolic remodeling in Food-induced anaphylaxis revealed by integrated proteomic and lipidomic analyses
D1.313 - Clinical Characteristics of Chronic Urticaria Patients With and Without Flares With Systemic Symptoms
D1.315 - IgE antibody function and mast cell activation to egg in children undergoing baked and loosely cooked egg challenges
D1.319 - Efficacy of Omalizumab in Refractory Cholinergic Urticaria and Cholinergic Anaphylaxis: A Case Series
D1.304 - Exercise-induced anaphylaxis misdiagnosed as cholinergic urticaria in a child: a case report
D1.308 - Severe Chronic Spontaneous Urticaria with Recurrent Anaphylaxis and Extreme IgE Elevation Associated with Innate Immune Dysregulation
D1.309 - The complexity of basal serum tryptase levels: Genotyping tryptase genes is not enough
D1.314 - Endothelial glycocalyx shedding in IgE- and IgG-mediated anaphylaxis
D1.316 - Identification of lipid classes to differentiate anaphylactic from non-anaphylactic allergic reactions. BANA study
D1.317 - Systemic inflammatory indices in relation to anaphylaxis symptoms in adults with food allergy
D1.320 - IgE-mediated Perioperative Anaphylaxis to Latex with Concomitant Local Anesthetic Hypersensitivity in a Mexican Teenager: a Policy-Changing Case Report
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download